

09/424181

PATENT COOPERATION TREATY

From the
INTERNATIONAL PRELIMINARY EXAMINING AUTHORITY

To: STEWART L. GITLER
HOFFMAN, WASSON & GITLER, PC
2361 JEFFERSON DAVIS HIGHWAY
SUITE 522
ARLINGTON, VA 22202

RECEIVE
APR - 9 1999
PCT
HOFFMAN, WASSON & GITLER, PC

NOTIFICATION OF TRANSMITTAL OF
INTERNATIONAL PRELIMINARY
EXAMINATION REPORT

(PCT Rule 71.1)

Date of Mailing
(day/month/year)

08 APR 1999

Applicant's or agent's file reference
A-5840.PCT

IMPORTANT NOTIFICATION

International application No. PCT/US98/09795	International filing date (day/month/year) 14 MAY 1998	Priority Date (day/month/year) 14 MAY 1997
---	---	---

Applicant

THE UNIVERSITY OF NEW MEXICO

1. The applicant is hereby notified that this International Preliminary Examining Authority transmits herewith the international preliminary examination report and its annexes, if any, established on the international application.
2. A copy of the report and its annexes, if any, is being transmitted to the International Bureau for communication to all the elected Offices.
3. Where required by any of the elected Offices, the International Bureau will prepare an English translation of the report (but not of any annexes) and will transmit such translation to those Offices.

4. REMINDER

The applicant must enter the national phase before each elected Office by performing certain acts (filing translations and paying national fees) within 30 months from the priority date (or later in some Offices)(Article 39(1))(see also the reminder sent by the International Bureau with Form PCT/IB/301).

Where a translation of the international application must be furnished to an elected Office, that translation must contain a translation of any annexes to the international preliminary examination report. It is the applicant's responsibility to prepare and furnish such translation directly to each elected Office concerned.

For further details on the applicable time limits and requirements of the elected Offices, see Volume II of the PCT Applicant's Guide.

Name and mailing address of the IPEA/US
Commissioner of Patents and Trademarks
Box PCT
Washington, D.C. 20231
Facsimile No. (703) 305-3230

Authorized officer
DAVID LUKTON
Telephone No. (703) 308-0196



PATENT COOPERATION TREATY

From the INTERNATIONAL BUREAU

PCT

NOTIFICATION OF ELECTION

(PCT Rule 61.2)

To:

United States Patent and Trademark
Office
(Box PCT)
Crystal Plaza 2
Washington, DC 20231
ÉTATS-UNIS D'AMÉRIQUE

in its capacity as elected Office

Date of mailing (day/month/year) 12 January 1999 (12.01.99)	Applicant's or agent's file reference A-5840.PCT
International application No. PCT/US98/09795	Priority date (day/month/year) 14 May 1997 (14.05.97)
International filing date (day/month/year) 14 May 1998 (14.05.98)	
<p>Applicant ROGELJ, Snezna et al</p>	

1. The designated Office is hereby notified of its election made:

in the demand filed with the International Preliminary Examining Authority on:

07 December 1998 (07.12.98)

in a notice effecting later election filed with the International Bureau on:

2. The election was

was not

made before the expiration of 19 months from the priority date or, where Rule 32 applies, within the time limit under Rule 32.2(b).

The International Bureau of WIPO 34, chemin des Colombettes 1211 Geneva 20, Switzerland Facsimile No.: (41-22) 740.14.35	Authorized officer Kari Huynh-Khuong Telephone No.: (41-22) 338.83.38
---	---

PATENT COOPERATION TREATY 09/424181

PCT

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

(PCT Article 36 and Rule 70)

Applicant's or agent's file reference A-5840.PCT	FOR FURTHER ACTION See Notification of Transmittal of International Preliminary Examination Report (Form PCT/IPEA/416)	
International application No. PCT/US98/09795	International filing date (day/month/year) 14 MAY 1998	Priority date (day/month/year) 14 MAY 1997
International Patent Classification (IPC) or national classification and IPC IPC(6): A61K 31/285 and US Cl.: 514/504		
Applicant THE UNIVERSITY OF NEW MEXICO		

1. This international preliminary examination report has been prepared by this International Preliminary Examining Authority and is transmitted to the applicant according to Article 36.


2. This REPORT consists of a total of 3 sheets.

This report is also accompanied by ANNEXES, i.e., sheets of the description, claims and/or drawings which have been amended and are the basis for this report and/or sheets containing rectifications made before this Authority. (see Rule 70.16 and Section 607 of the Administrative Instructions under the PCT).

These annexes consist of a total of 5 sheets.

3. This report contains indications relating to the following items:

- I Basis of the report
- II Priority
- III Non-establishment of report with regard to novelty, inventive step or industrial applicability
- IV Lack of unity of invention
- V Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement
- VI Certain documents cited
- VII Certain defects in the international application
- VIII Certain observations on the international application

Date of submission of the demand 07 DECEMBER 1998	Date of completion of this report 11 MARCH 1999
Name and mailing address of the IPEA/US Commissioner of Patents and Trademarks Box PCT Washington, D.C. 20231	Authorized officer DAVID LUKTON Telephone No. (703) 308-0196
Facsimile No. (703) 305-3230	

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

International application No.

PCT/US98/09795

L Basis of the report

1. This report has been drawn on the basis of (Substitute sheets which have been furnished to the receiving Office in response to an invitation under Article 14 are referred to in this report as "originally filed" and are not annexed to the report since they do not contain amendments):

the international application as originally filed.

the description, pages 1-26, as originally filed.

pages NONE, filed with the demand.

pages NONE, filed with the letter of _____.

pages , filed with the letter of _____.

the claims, Nos. 1-19, as originally filed.

Nos. NONE, as amended under Article 19.

Nos. NONE, filed with the demand.

Nos. NONE, filed with the letter of _____.

Nos. , filed with the letter of _____.

the drawings, sheets/fig 1-6, as originally filed.

sheets/fig NONE, filed with the demand.

sheets/fig NONE, filed with the letter of _____.

sheets/fig , filed with the letter of _____.

2. The amendments have resulted in the cancellation of:

the description, pages NONE.

the claims, Nos. NONE.

the drawings, sheets/fig NONE.

3. This report has been established as if (some of) the amendments had not been made, since they have been considered to go beyond the disclosure as filed, as indicated in the **Supplemental Box**. Additional observations below (Rule 70.2(c)).

4. Additional observations, if necessary:

NONE

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

International application No.

PCT/US98/09795

V. Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement**1. STATEMENT**

Novelty (N)	Claims <u>1-19</u>	YES
	Claims <u>NONE</u>	NO
Inventive Step (IS)	Claims <u>1-19</u>	YES
	Claims <u>NONE</u>	NO
Industrial Applicability (IA)	Claims <u>1-10</u>	YES
	Claims <u>NONE</u>	NO

2. CITATIONS AND EXPLANATIONS

Claims 1-19 meet the criteria set out in PCT Article 33(2)-(4), because the prior art does not teach or fairly suggest the claimed compounds or methods of using them.

----- NEW CITATIONS -----
NONE

PATENT COOPERATION TREATY

From the INTERNATIONAL SEARCHING AUTHORITY

To: JEAN A. BUTTMI
HOFFMAN, WASSON & GITLER, PC
2361 JEFFERSON DAVIS HIGHWAY
SUITE 522
ARLINGTON, VA 22202

PCT SEP 28 1998
noted

NOTIFICATION OF TRANSMITTAL OF THE INTERNATIONAL SEARCH REPORT OR THE DECLARATION

(PCT Rule 44.1)

		Date of Mailing (day/month/year)
Applicant's or agent's file reference A-5840.PCT	FOR FURTHER ACTION See paragraphs 1 and 4 below	
International application No. PCT/US98/09795	International filing date (day/month/year) 14 MAY 1998	
Applicant THE UNIVERSITY OF NEW MEXICO		

1. The applicant is hereby notified that the international search report has been established and is transmitted herewith.

Filing of amendments and statement under Article 19:

The applicant is entitled, if he so wishes, to amend the claims of the international application (see Rule 46):

When? The time limit for filing such amendments is normally 2 months from the date of transmittal of the international search report; however, for more details, see the notes on the accompanying sheet.

Where? Directly to the International Bureau of WIPO

34, chemin des Colombettes
1211 Geneva 20, Switzerland
Facsimile No.: (41-22) 740.14.35

For more detailed instructions, see the notes on the accompanying sheet.

2. The applicant is hereby notified that no international search report will be established and that the declaration under Article 17(2)(a) to that effect is transmitted herewith.

3. With regard to the protest against payment of (an) additional fee(s) under Rule 40.2, the applicant is notified that:

- the protest together with the decision thereon has been transmitted to the International Bureau together with the applicant's request to forward the texts of both the protest and the decision thereon to the designated Offices.
- no decision has been made yet on the protest; the applicant will be notified as soon as a decision is made.

4. Further action(s): The applicant is reminded of the following:

Shortly after 18 months from the priority date, the international application will be published by the International Bureau. If the applicant wishes to avoid or postpone publication, a notice of withdrawal of the international application, or of the priority claim, must reach the International Bureau as provided in rules 90 bis 1 and 90 bis 3, respectively, before the completion of the technical preparations for international publication.

Within 19 months from the priority date, a demand for international preliminary examination must be filed if the applicant wishes to postpone the entry into the national phase until 30 months from the priority date (in some Offices even later).

Within 20 months from the priority date, the applicant must perform the prescribed acts for entry into the national phase before all designated Offices which have not been elected in the demand or in a later election within 19 months from the priority date or could not be elected because they are not bound by Chapter II.

Name and mailing address of the ISA/US Commissioner of Patents and Trademarks Box PCT Washington, D.C. 20231 Facsimile No. (703) 305-3230	Authorized officer <i>David Lukton</i> DAVID LUKTON Telephone No. (703) 308-0196
---	---

(See notes on accompanying sheet)

PATENT COOPERATION TREATY

From the INTERNATIONAL SEARCHING AUTHORITY

To: JEAN A. BUTTMI
 HOFFMAN, WASSON & GITLER, PC
 2361 JEFFERSON DAVIS HIGHWAY
 SUITE 522
 ARLINGTON, VA 22202

PCT

NOTIFICATION OF TRANSMITTAL OF THE INTERNATIONAL SEARCH REPORT OR THE DECLARATION

(PCT Rule 44.1)

Date of Mailing
 (day/month/year)

23 SEP 1998

Applicant's or agent's file reference A-5840.PCT	FOR FURTHER ACTION See paragraphs 1 and 4 below
International application No. PCT/US98/09795	International filing date (day/month/year) 14 MAY 1998
Applicant THE UNIVERSITY OF NEW MEXICO	

1. The applicant is hereby notified that the international search report has been established and is transmitted herewith.

Filing of amendments and statement under Article 19:

The applicant is entitled, if he so wishes, to amend the claims of the international application (see Rule 46):

When? The time limit for filing such amendments is normally 2 months from the date of transmittal of the international search report; however, for more details, see the notes on the accompanying sheet.

Where? Directly to the International Bureau of WIPO

34, chemin des Colombettes
 1211 Geneva 20, Switzerland
 Facsimile No.: (41-22) 740.14.35

For more detailed instructions, see the notes on the accompanying sheet.

2. The applicant is hereby notified that no international search report will be established and that the declaration under Article 17(2)(a) to that effect is transmitted herewith.

3. With regard to the protest against payment of (an) additional fee(s) under Rule 40.2, the applicant is notified that:

the protest together with the decision thereon has been transmitted to the International Bureau together with the applicant's request to forward the texts of both the protest and the decision thereon to the designated Offices.
 no decision has been made yet on the protest; the applicant will be notified as soon as a decision is made.

4. **Further action(s):** The applicant is reminded of the following:

Shortly after 18 months from the priority date, the international application will be published by the International Bureau. If the applicant wishes to avoid or postpone publication, a notice of withdrawal of the international application, or of the priority claim, must reach the International Bureau as provided in rules 90 bis 1 and 90 bis 3, respectively, before the completion of the technical preparations for international publication.

Within 19 months from the priority date, a demand for international preliminary examination must be filed if the applicant wishes to postpone the entry into the national phase until 30 months from the priority date (in some Offices even later).

Within 20 months from the priority date, the applicant must perform the prescribed acts for entry into the national phase before all designated Offices which have not been elected in the demand or in a later election within 19 months from the priority date or could not be elected because they are not bound by Chapter II.

Name and mailing address of the ISA/US
 Commissioner of Patents and Trademarks
 Box PCT
 Washington, D.C. 20231
 Facsimile No. (703) 305-3230

Authorized officer
 DAVID LUKTON
 Telephone No. (703) 308-0196



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : A61K 31/285		A1	(11) International Publication Number: WO 98/51297 (43) International Publication Date: 19 November 1998 (19.11.98)
<p>(21) International Application Number: PCT/US98/09795</p> <p>(22) International Filing Date: 14 May 1998 (14.05.98)</p> <p>(30) Priority Data: 60/046,487 14 May 1997 (14.05.97) US</p> <p>(71) Applicant (for all designated States except US): THE UNIVERSITY OF NEW MEXICO [US/US]; Albuquerque, NM 87131 (US).</p> <p>(72) Inventors; and</p> <p>(75) Inventors/Applicants (for US only): ROGELJ, Snezna [US/US]; 705 Sunset Street, Socorro, NM 87801 (US). SKLAR, Larry, A. [US/US]; 4000 Aspen Avenue N.E., Albuquerque, NM 87110 (US).</p> <p>(74) Agents: BUTTMI, Jean, A. et al.; Hoffman, Wasson & Gitler, PC, Suite 522, 2361 Jefferson Davis Highway, Arlington, VA 22202 (US).</p>		<p>(81) Designated States: CA, JP, US, European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).</p> <p>Published <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i> </p>	
<p>(54) Title: INHIBITION OF CELL SURFACE PROTEIN DISULFIDE ISOMERASE</p> <p>(57) Abstract</p> <p>The invention provides anti-thiol reagents which inhibit enzyme activity of cell-associated protein disulfide isomerase (PDI) by oxidizing or blocking PDI active site vicinal thiol groups which normally participate in disulfide bond rearrangement of PDI substrates. Inhibition of this PDI function is particularly useful in blocking PDI-mediated entry of HIV or other virions into a host cell. The invention further provides an assay for the identification of such PDI inhibitors based on the discovery that inhibitors of the invention also induce shedding of the leucocyte L-selectin adhesion molecule.</p>			

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav	TM	Turkmenistan
BF	Burkina Faso	GR	Greece		Republic of Macedonia	TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's	NZ	New Zealand		
CM	Cameroon		Republic of Korea	PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakhstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

INHIBITION OF CELL SURFACE PROTEIN DISULFIDE ISOMERASE**BACKGROUND OF THE INVENTION**

5. The invention relates to anti-thiol reagents which inhibit enzyme activity of cell-associated protein disulfide isomerase (PDI) by oxidizing or blocking PDI active site vicinal thiol groups which normally participate in disulfide bond rearrangement of PDI substrates. Inhibition of this PDI function
10 is particularly useful in blocking PDI-mediated entry of HIV or other virions into a host cell.

15 The invention further relates to an assay for the identification of such PDI inhibitors based on the discovery that inhibitors of the invention also induce shedding of the leucocyte L-selectin adhesion molecule.

1. Field of Art:

20 Cell-associated PDI (protein disulfide isomerase) is a constitutive cellular protein abundantly expressed on the surface of many mammalian cell types, including immune system cells, hepatocytes, and platelets. Like other members of the
25 thyredoxin superfamily of proteins, PDI is a multifunctional redox-sensitive protein that catalyzes oxidation-reduction reactions via a vicinal dithiol-dependent disulfide-sulfhydryl interchange between its internal vicinal dithiol (Cys-Gly-His-Cys) active sites and the disulfide bonds of its substrates to promote their reconfiguration. PDI recognizes the side chains
30 of cysteine residues in its substrates, and it is its two vicinal dithiol groups, one on each of two identical PDI subunits, that are critical for its enzymatic isomerase function, in particular its broad specificity for correcting the configuration of a large spectrum of proteins as needed. For example, PDI is present in the endoplasmic reticulum of most cells, where it is believed to
35 mediate co- and post- translational modifications of nascent proteins with incorrect sulfide bonds; it is also present in certain protein complexes such as triglyceride transfer protein

complex (MTP) wherein it maintains the complex in a catalytically-active state and inhibits complex aggregation. Membrane PDI catalyzes the cleavage of disulfide bonds during the earliest stages of endocytosis, and activates diphtheria toxin by catalyzing cleavage of this disulfide-linked dimer. PDI also catalyzes the isomerization of thrombospondin (TSP) disulfide bonds, thereby profoundly modulating TSP ligand binding activity. Both TSP and PDI are released by activated platelets; PDI is also released by degranulated neutrophils (*J. Cell Physiol.* 144: 280, 10 1990).

Other known PDI functions include the recognized ability of PDI to modulate certain cell adhesive interactions. While PDI isomerase activity affects, for example, the adhesive properties of TSP, PDI is additionally a "chaperone" for some proteins by means independent of its catalytic activity. One of these chaperone functions has been attributed to PDI binding complex formation with proteins which have a tendency to aggregate in the denatured state. Association with PDI prevents this aggregation by promoting appropriate folding of the associated protein. PDI in MTP complexes inhibits MTP aggregation, and a PDI homolog (cognin) plays a role in the adhesion-dependent aggregation of retinal cells.

2. Discussion of Related Art.

25 Of particular relevance to the present inventions is the involvement of PDI in the shedding of the human thyrotropin (TSH) receptor ectodomain (*Biochem.* 35:14800, 1996). In a two-step process, a matrix metalloproteinase first cleaves the 30 receptor into two subunits (an α -extracellular subunit and a β -transmembrane subunit) linked by a disulfide bridge. The α -extracellular subunit is then shed from the cell membrane as a result of PDI-mediated reduction of the disulfide bridge(s) connecting it to the β -transmembrane subunit. However, in 35 contrast to the PDI-mediated L-selectin shedding mechanism according to the present invention, the TSH shedding mechanism requires PDI isomerase activity, and inhibition of PDI activity

with known PDI inhibitors such as DTNB (5,5'-dithiobis (2-nitrobenzoic acid), bacitracin, or anti-PDI antibodies prevents the shedding (release) of the TSH α -subunit.

Also of relevance is the known ability of PDI to 5. mediate transmembrane carriage of proteins and virions into cells by rearrangement of their disulfide bonds. For example, the attachment of HIV to its host cell surface receptor CD4 via the viral glycoprotein gp 120 is triggered by a conformational change in gp 120/gp 41 resulting from a rearrangement of its critical 10 disulfide bonds as catalyzed by PDI. Known PDI inhibitors (e.g., bacitracin, anti-PDI antibodies) block HIV entry into the cell cytoplasm to some extent, but they are very weak inhibitors of PDI isomerase activity in this clinical application (PNAS USA 91: 4559, 1994). The use of another known PDI inhibitor, DTNB 15 (supra) to inhibit viral penetration into cells has been described (U.S. Patent 5,532,154 to Brown); however, the recited activity of this compound in preventing HIV entry into cells is attributed by the patentee to inactivation of "virus-derived thiol reductase/protein disulfide isomerase", presumably encoded 20 by and present on the virus itself.

The interaction of arsine oxide with certain proteins having active vicinal dithiol sites which undergo catalytic conversion to disulfides to form stable dithioarsenic derivatives is described in Anal. Biochem 212: 325-334 (1993). This 25 reactivity was used by the authors to separate dithiols from monothiols and also from dithiol-containing proteins with low-affinity for arsene oxide.

BRIEF DESCRIPTION OF THE DRAWINGS

5 **FIG. 1. Regulation of L-selectin shedding.** Reduced cell surface PDI constitutively maintains L-selectin in the reduced, non-cleavable conformation. Chemical blockade or direct oxidation of the PDI vicinal dithiol active sites leads to a formation of a critical disulfide bridge within L-selectin molecule. The resulting conformation of L-selectin permits cleavage by the sheddase. In the presence of TAPI, L-selectin 10 shedding is blocked.

FIG. 2. Induction of L-selectin shedding with PAODMPS*.

15 **FIG. 3. Effect of PAO, PAO* and BESA on L-selectin shedding from human neutrophils.**

20 **FIG. 4. Effect of PAO on neutrophil adhesion molecules**
(a) PAO induces L-selectin shedding from neutrophils in a dose dependent manner. Control-4°C represents a neutrophil population that has remained at 4°C since isolation. L-selectin levels were normalized, with the expression on the Control-4°C population representing 100%. Control - 10 min. @ 37°C is an untreated population that underwent a mock 10 minute incubation along with the PAO and fMLP treated cells. **(b)** A phenotypic analysis of PAO 25 treated neutrophils. 100nM PAO does not appreciably upregulate Mac-1 or induce the shedding of other cell surface molecules known to undergo proteolytic cleavage. The mean channel number of fluorescence is reported with the S.E.M. Experiments were performed twice with duplicate or triplicate samples done in each. **(c)** Activity in whole blood. Peripheral venous blood was 30 diluted with 1:10 with HHB buffer and treated with 1 μ M PAO for 20 minutes at 37°C. L-selectin expression was measured by the subsequent FACScan analysis of the LDS-751 and Leu8-FITC labeled cells.

SUMMARY OF THE DISCLOSURE

5 The inventions provide cell-surface protein disulfide isomerase (csPDI) inhibitors which block PDI-mediated disulfide rearrangement in PDI substrates. In particular, the inventions provide (di)thiol-reactive reagents which react with active site vicinal dithiols of csPDI to inhibit the substrate disulfide bond rearrangement prerequisite for entry of the substrate into the cell.

10 The inventions are in part predicated on the discovery that inhibitors according to the invention also promote shedding of the leucocyte adhesion molecule L-selectin, and screening protocols for identification of inhibitors within the scope of the invention based on this phenomenon are accordingly further provided.

15 The inhibitors of the invention are particularly useful for denying viruses requiring disulfide bond rearrangement for transmembrane passage to access host cell DNA for replication. The inventions accordingly provide methods for inhibiting replication of such viruses, notably gag retroviruses including HIV virotypes, by disrupting their PDI-mediated cell entry mechanisms.

20 The inventions additionally provide a two-pronged approach for prevention and treatment of PDI-mediated viral infection based on the observed contemporaneous inducement of L-selectin shedding and the inhibition of viral cell entry by the inhibitors of the invention.

25 Pharmaceutical compositions containing the inhibitors of the invention and methods for treating or preventing viral infection in humans or other mammals, including periodic elevations of HIV or other viremia are also provided. Combinations of these compositions and methods with other viral therapies is useful.

DETAILED DESCRIPTION OF THE INVENTION

According to the invention, cell-surface PDI (csPDI) isomerase activity is effectively inhibited by thiol blocking agents (inhibitors) which covalently or non-covalently cross-link two or more free vicinal sulfhydryl groups of one or more PDI active site peptide sequences to form complexes stable in the cell environment. The - SH groups of the cysteine residues in the sequence Cys-Gly-His-Cys are exemplary. The inhibitors are 5 preferably highly selective for PDI vicinal sulfhydryls and have sufficient affinity for these groups to compete successfully with the ligand to be denied access to these sites and prevent PDI-mediated isomerization of its disulfide bonds and its 10 consequent reconfiguration for undesired biological activity. 15 The sequence of PDI is known (Nature 317:6034; 267, 1985). Herein, "csPDI" and "PDI" are used interchangeably unless otherwise noted.

Inhibitors according to the invention are useful for 20 inhibiting thiol-mediated csPDI isomerase activity with proper selection of inhibitors, and possibly one or more non-isomerase activities, such as the afore-mentioned "chaperone" activity. This includes both presently-known PDI isomerase and other 25 activities and other cell-associated PDI activities yet to be discovered.

In one embodiment, the PDI inhibitors of the invention 30 inhibit virion cell entry mediated by csPDI expressed on the plasma membrane of potential host cells, particularly gag retroviruses such as HIV viotypes. As described in further detail below, PDI inhibitors useful for this application can be directly identified by appropriate NIH protocols such as those 35 described for HIV infra. Alternately, according to the invention, potentially useful PDI inhibitors are identified by screening for their ability to inhibit L-selectin shedding. The ability of the L-selectin shedding assay of the invention (Examples) to identify inhibitors of thiol-mediated csPDI activity is demonstrated in detail infra. This assay is based on the observation that a blockade of leucocyte csPDI oxido-

5 reductive function induces a release of L-selectin, a cell surface adhesion molecule, and that the rate of L-selectin release is a direct reflection of the efficacy of the csPDI inhibitor. Therefore, measuring the amount of L-selectin released from leucocytes within a certain time period provides information regarding the potency of the putative csPDI inhibitor.

10 A detailed description of L-selectin shedding phenomena is given in J. Immun. 156:3093-3097, 1996, incorporated herein by reference. Briefly, the L-selectin adhesion molecule mediates leucocyte recruitment to inflammatory sites and lymphocyte trafficking through the peripheral lymph nodes. In response to leucocyte activation, L-selectin is proteolytically released (shed) from the cell surface, disabling leucocytes from the 15 subsequent L-selectin-dependent interactions. L-selectin shedding is sensitive to sulfhydryl chemistry and PDI regulates the susceptibility of leucocyte L-selectin to shedding promoted by (di)thiol oxidizing or blocking reagents according to the invention. In contrast to known prior art shedding mechanisms 20 such as those for TSH (*supra*), csPDI constitutively acts on L-selectin to maintain its disulfide bonds in a reduced, non-cleavable state; blockade of PDI permits reversion of these bonds to the oxidized, cleavable conformation for shedding. Thus, 25 shedding is promoted by the instant inhibitors in direct relationship to the effect of the inhibitors on blocking csPDI function (FIG. 1). Since L-selectin is also present on lymphocytes and mediates their entry into peripheral lymph nodes, L-selectin shedding according to the invention also inhibits the movement of virally-infected lymphocytes into these nodes, 30 preventing the establishment of viral reservoirs responsible for spreading the infection to uninfected lymphocytes. In chronically infected individuals, the inhibition of nascent, uninfected lymphocyte trafficking through the lymph node viral reservoirs would further prevent the exposure of these cells to 35 the virus, and therefore the internal spread of HIV. Finally, by inducing the shedding of lymphocyte L-selectin, these reagents

would ameliorate the lymphadenopathy thought to be due to an increase in L-selectin expression, and therefore homing to the lymph nodes, by the abortively HIV-infected lymphocytes.

PAO (phenylarsine oxide), a trivalent arsenical inhibitor of the invention interacts with PDI vicinal dithiols and is most potent in inducing rapid shedding of L-selectin from isolated neutrophils, eosinophils, and lymphocytes, as well as from neutrophils in whole blood. PAO does not cause cell activation, nor does it interfere with integrin function or alter the expression of several other cell surface molecules at the lower concentrations that effectively induce L-selectin shedding. Further, PAO is not required to enter the cell to induce L-selectin shedding. TAPI, which has previously been shown to inhibit activation-dependent L-selectin shedding, is also capable of inhibiting PAO-induced L-selectin shedding. The Snežna L-Selectin Assay of the invention has been validated with human leucocytes but is anticipated to work as well with leucocytes of other species. In all cases, species-specific anti-L-selectin antibodies should be used for labeling. Although the assay can be carried out with either neutrophils or with lymphocytes, neutrophils appear to provide a faster and a more sensitive L-selectin shedding response. PDI inhibitors identified by this protocol are useful in the inhibition of PDI according to the present invention.

Inhibitors of the invention comprise agents which form stable complexes or derivatives by covalent or non-covalent binding with one or more active thiol groups of PDI to inhibit catalytic rearrangement of substrate disulfide groups. Both monothiol inhibitors (which inactivate single thiol groups) and dithiol inhibitors (which cross-link two thiol groups) are useful, especially inhibitors specific to PDI vicinal sulfhydryl groups, and act by blocking or oxidizing the groups. Preferred inhibitors for in vivo use comprise membrane impermeable inhibitors [denoted herein with an asterisk (*)], as this avoids toxicity resulting from undesirable effects of cell-permeable inhibitors on intra-cellular processes. More preferred for in

vivo uses are asterisked inhibitors efficacious in evaluation protocols at relatively low concentrations (i.e., concentrations with respect to each other).

Typically, dithiol inhibitors will have greater efficacy as inhibitors, as they have been found to have greater potency at lower concentrations. This is important, as many of the inhibitors are potentially toxic to cells at high concentrations, especially cell-permeable inhibitors. Vicinal dithiol-reactive inhibitors will have a preference for the vicinal (closely spaced) dithiol (reduced cysteine) sites such as those found in the active sites of PDI. It is known that the dithiol-reactive reagents are much less likely to interact with monothiol sites. (Reactivity with monothiol sites should generally be avoided as it would lead to loss of specificity and an increase in cytotoxicity.) Dithiol reactivity thus enhances specificity and potency while minimizing cytotoxicity. Using dithiol reagents such as PAO derivatives offers an additional advantage: they can be selectively removed from a target protein such as PDI with DMP (British Anti-Lewisite, a clinically-known heavy metal antidote) or the related (membrane-impermeable) DMPS, once the desired effect has been achieved. Such a reversal can be carried out if PAO(*) toxicity becomes an issue and PAO(*) needs to be flushed-out from the patient.

Exemplary inhibitors useful in the practice of the invention are set forth in TABLE I, below.

TABLE I

COMPOUNDS THAT INDUCE L-SELECTIN SHEDDING FROM NEUTROPHILS

100% LOSS from cell surface in 10 min at 37 deg. at
the approximate concentration:

5 (membrane-impermeable inhibitors are marked with *)

Thiol Blocking and Oxidizing reagents

10	PAO.....	-1 uM - vicinal dithiol specific
	PAO-DNP.....	-1 uM - DNP added far from AsO group
	Aminophenylmercuric acetate.....	10 uM - monothiol reactives activates MMPs
	Nitroblue tetrazolium.....	100 uM - superoxide scavenger and oxidant
15	Hydrogen peroxide.....	150 uM - oxidant, effect inhibitable by excess DMPS
	Monobromobimane mBBr.....	100 uM - thiol blocker (fluorescent as bound)
	Dibromobimane bBBr.....	100 uM - dithiol reactive, spacing differs from PAO
20	*DIDS.....	200 uM - thiol and amino-group reactive
	N-ethylmaleimide.....	250 uM - thiol blocker
	* Quaternary bromobimane qBBr...	300 uM - membrane-impermeable mBBr
	Iodoacetate IA.....	300 uM - thiol blocker, also depletes energy
25	*Mersalyl acid.....	500 uM - thiol-reactive via - HgOH
	Thimerosal.....	500 uM - thiol blocker, used as preservative
	*DTNB.....	1 mM - thiol-blocker
30	PMSF.....	1 mM - attacks and blocks - SH (and OH) groups
	Diamide.....	1 mM - thiol oxidizer/crosslinker, ADA analog
	Azodicarbonamide.....	1 mM - blocks HIV infectivity, flour additive
35	Iodoacetamide.....	10 mM - thiol reagent, low efficacy (vs. IA) surprising
	Iodosobenzoate.....	1 mM - A dithiol oxidizing reagent just like PAO, but with Iodine instead of arsenic, causes direct oxidation of dithiols
40		

Dithiol Reactive Ions:

45	Arsenic (As2O3).....	50 uM
	Cadmium (CdCl2).....	1 mM
	Antimony (Sb2O3).....	50 uM

Other Reagents and Conditions:

5	*Dehydroascorbate.....	1 mM	- specifically and only reduced by PDI or glutaredoxin, would lead to net oxidation of PDI
10	Chlorpromazine.....	50 mM	- blocks HIV infectivity at this concentration
15	Methoxychlor.....	50 uM	- a pesticide, a calmodulin antagonist
20	DDT.....	50 uM	- a pesticide, a calmodulin Antagonist
	Disulfiram (Antabuse).....	50 uM	- drug that induces alcohol aversion
	*Thioredoxin.....	50 ug/ml	- reductant at cell surface, poor isomerase, has biphasic effect on shedding
	*Protein Disulfide Isomerase....	20 ug/ml	- effective isomerase at cell surface
	Somatostatin.....	200 uM	- peptide PDI inhibitor
	UV irradiation.....	10 min	- produces ROS, effect TAPI inhibitable

25 As alluded to supra, the inhibitors of the invention are especially useful in vivo for blocking entry of virions into targeted host cells by blocking an essential PDI-mediated step of their transmembrane process. Since some of the inhibitors useful in this process such as PAO also inhibit L-selectin shedding from lymphocytes and thus lymphocyte entry into 30 peripheral lymph nodes, the establishment of reservoirs of transfected lymphocytes is concurrently inhibited. This is an important advantage when treating viral infections characterized by lymphocyte infection such as HIV, since HIV-infected cells can each produce billions of virions daily and it is the subsequent 35 entry of these virions into uninfected cells which propagates the disease.

40 Most of the inhibitors identified by the inventors to date, including cadmium, and trivalent arsenical and antimonial compounds work by blocking the vicinal cysteines in PDI active sites; however, some inhibitors may work by blocking PDI activity by a mechanism that is different from the thiol-mediated blockade 45 of the Cys-Gly-His-Cys active sites. The inhibitors are generally not cell-specific (unlike, for example, fMLP for which CHO and lymphocytes are receptor negative), and are selected as the application requires as described herein. Cell-membrane

impermeable inhibitors are typically selected for applications requiring minimization of toxicity as are the dithiol and dithiol-specific inhibitors, as these tend to be efficacious at lower relative concentrations. Monothiol and/or cell-membrane permeable inhibitors are, however, useful in the practice of the invention and may prove equal or superior to dithiol inhibitors in applications where a slight increase in cell toxicity is not a critical factor.

Pharmaceutical compositions containing the inhibitors of the invention are useful as prophylactics for immediate treatment on exposure to HIV or other PDI-dependent virus and for treating established viral infection, including periodic elevations of HIV or other viremia. Treatment according to the invention with other therapies is contemplated.

Compositions for parenteral administration comprise aqueous solutions of the inhibitors of the invention in an amount sufficient to provide a blood concentration of about $1\mu\text{M}$ or less in whole blood. More potent inhibitors are contemplated to be effective at concentrations of about $0.1\mu\text{M}$ or less. Suitable concentrations are readily determined by combining an inhibitor with a blood sample and selecting a concentration that induces PDI shedding from leucocytes, usually within about 20 minutes to 2 hours, depending upon inhibitor concentration. For intravenous administration, compositions comprising inhibitor and (at least mostly) water as solvent in concentrations of about 35 mg/solvent are generally effective.

For example, 1 μM PAO (i.e., about 0.17 mg PAO/liter of blood) blocks PDI in whole human blood to the extent that 50% L-selectin shedding from neutrophils is induced in about 20 min. 10 μM (i.e., about 1.7 mg PAO/liter of blood) should induce complete shedding within about 20 min. Thus, administering sufficient PAO to attain 10 μM concentration of PAO in blood should fully block leucocyte csPDI. Since only a fraction of total body weight is blood (assume 10 liters in a 50 kg human), then 17 mg of PAO is required for this effect. This translates to 17 mg/50 kg or about 0.35 mg PAO/kg body weight. A 100 kg human thus would require about 35 mg of PAO to attain

"instantaneous" 10 uM blood concentration. PAO at these low concentrations is soluble in most aqueous media (the initial high concentration stock in DMSO can be diluted into aqueous buffer for in vivo use).

5 A recommended procedure for in vivo administration of PAO comprises preparing an injectable (for example, i.v.) aqueous stock of PAO containing 35 mg PAO/ml PBS. Depending on the weight of the patient, an appropriate volume is injected (e.g., a 70 kg person would receive about 0.7 ml of the preparation).
10 To avoid local toxicity, this stock preparation can be diluted further and proportionally larger volume injected slowly to attain the same blood concentrations in a comparable period of time.

15 Similar calculations are carried out for the various PAO* inhibitors. Based on the predetermined concentration required to induce full shedding of L-selectin in whole blood. For example, 10 uM PAO* is required to obtain about the same results as 1 uM PAO, in whole blood. The required concentrations for treatment are thus 10 times higher, i.e., 3.5 mg PAO*/kg body weight. The injectable stock preparation should then be made up as 350 mg PAO*/ml PBS; a 70 kg human would need 0.7 ml of this stock preparation. In practice, lower concentrations might suffice, as these are high-end estimates. Concentrations should be kept to a minimum sufficient for effectiveness to minimize 20 toxicity.

25 Of great advantage is that the inhibitors are readily soluble in aqueous media at the concentrations needed for effective administration for inhibiting PDI isomerase activity and/or virion entry into cells. Compositions can also be 30 administered orally; oral compositions comprising excipient(s) and inhibitor in amounts which provide blood concentrations as described above are useful in the practice of the invention.

EXAMPLES**I. Detection of L-selectin release:**

5 L-selectin release can be measured either as a loss of L-selectin from the cell surface using a fluorescence activated cell sorter (FACS), or it can be measured as an increase of the released, soluble L-selectin in the cells' supernate (using, for example, an ELISA).

10 A) Using FACS Analyzer:

15 Using this method, cell-associated L-selectin is measured. Using fluorescently labeled anti-L-selectin antibody, the cell surface L-selectin is tagged. PDI inhibition causes L-selectin and its tag to be released from the cell surface. This results in a loss of cell-associated fluorescence.

20 These are two, essentially equivalent, methods for detecting the release of L-selectin from leucocyte cell surfaces.

25 1) In the first method, cells are first treated with the inhibitor and then samples are labeled individually for L-selectin that remains on the cell surface. In the second method, the cells are prelabeled with fluorescent anti-L-selectin antibody and then treated with the putative PDI inhibitor. Prelabeling of the cells has only a minor accelerating effect on L-selectin shedding when the treatment times are in the range of 10 min. The temperature control sample, lacking any drug treatment, reflects this "spontaneous" shedding when compared with a prelabeled sample that was kept on ice. This method, however, permits the preparation of a large volume of uniformly prelabeled substrate cells for the assay, minimizes inter-sample variation, and is less labor intensive. Prelabeling of cells with fluorescent anti-L-selectin antibody does not interfere with PDI inhibition or L-selectin shedding.

30 In either case, the cells are labeled with fluorescent (e.g., FITC or PE) anti-L-selectin antibody on ice for 45 minutes at a concentration in the range of 1 μ g/ml (see specific example below).

B) Using a soluble L-selectin (sL-selectin) ELISA.

This assay was validated using the Bender MedSystems (Boehringer Ingelheim Group, Vienna, Austria) sL-selectin ELISA kit. However, a much better source of sL-selectin ELISA kits is Endogen (Endogen, Inc. Woburn, MA). Measuring sL-selectin using ELISA rather than the FACScan analysis is a much more convenient method for screening large numbers and concentrations of various putative PDI inhibitors. Moreover, smaller numbers of leucocytes are required for this method. The one advantage of FACScan analysis over the ELISA is that toxicity to the cells is readily noted on the FSC/SSC FACScan output. Since acute toxicity could result in a PDI-independent loss of L-selectin release, selected sample analysis should be confirmed using the FACScan method.

Final validation of reagent PDI inhibitory activity is carried out *inter alia*, using purified PDI protein (Sigma) and one of the several standard PDI activity assays. One example of such an established PDI assay is based on the ability of PDI to renature, and thus restore activity to, RNase A with scrambled disulfide bonds (Sigma) (Methods in Enzymology. 251:397-406, 1995). Only properly disulfide-bonded RNase A is able to degrade RNA. The increase in absorbance at 260nM is the reflection of RNase activity. A control reaction mix containing only scrambled RNase without PDI provides for a measure of the uncatalyzed RNase renaturation. PDI inhibitors abolish RNase renaturation and are displayed as a loss of 260nM absorbance as compared to control. This method, while highly specific and accurate, is very labor intensive and would prove very expensive for large-scale screening purposes.

II. Preparation of PDI inhibitors:

The putative PDI inhibitors are preferably dissolved in an aqueous solvent. PAO solutions (10mM stock) are prepared in DMSO (Sigma Chemical Co.) and gently heated until PAO goes into solution. Other potential inhibitors of PDI are also dissolved in DMSO. DMSO concentration in the assays should not exceed 1% final volume; above this concentration, DMSO may affect

L-selectin shedding. Dioxane should not be used, as it itself induces L-selectin release.

III. Discrimination between PDI inhibition and cell activation:

Activation of neutrophils with a number of biologicals such as fMLP, PAF or LPS, results in the shedding of L-selectin in a manner that does not depend on a direct blockade of PDI activity. Since cell surface increase of Mac-1 integrin, a cell adhesion molecule, (CD18/CD11b) is characteristic of cell activation, reagents which act directly on PDI should not promote the upregulation of Mac-1 on neutrophils. The levels of Mac-1 can readily be measured by flow cytometry using fluorescently labeled anti-Mac-1 antibodies. Useful PDI inhibitors are preferably not cell-type specific. For example, fMLP and LPS only affect neutrophils but not lymphocytes, while preferred PDI inhibitors affect L-selectin shedding from both cell types.

KNOWN CONCEPTS:

1) Direct assay for measuring purified PDI activity. (Freeman RB, Hawkins HC, and McLaughlin SH, 1995 "Protein Disulfide Isomerase", Methods in Enzymology 251:397-406, 1995 incorporated herein by reference).

5 2) Flow cytometric analysis of cell associated L-selectin. (Bennet TA, Lynam EB, Sklar LA, and Rogelj S. "Hydroxamate-base metalloprotease inhibitor blocks shedding of L-selectin adhesion molecule from leucocytes; functional consequences for neutrophil aggregation", J. Immunol. 156(9):3093-7, 1996, incorporated herein by reference).

10 3) ELISA for quantitation of soluble L-selectin. (Spertini O, Schleiffenbaum B, White-Owen C, Ruiz P Jr., and Tedder TF, "ELISA for quantitation of L-selectin shed from leucocytes in vivo." J. Immunol Methods 156(1):115-23, 1992, incorporated herein by reference).

EXAMPLE I

15 Neutrophil or lymphocyte isolation: Human venous blood was collected from healthy volunteers into sterile syringes containing heparin (10U/ml blood, Elkins-Simms Inc., Cherry Hill, NJ). The blood was separated on Mono-Poly resolving media (ICN Biochemicals, Aurora, OH) by centrifugation of 500g for 22 minutes at 12°C. The granulocyte and mononuclear (for lymphocytes) layers were collected separately and washed in HHB buffer (110mM NaCl, 10mM KC1, 10mM glucose, 1mM MgCl₂ and 30 mM HEPES, pH 7.40), then pelleted at 400g for 10 minutes. The cells were resuspended in HHB buffer containing 0.1% human serum albumin (HSA; Armour Pharmaceutical Co., Kankakee, IL) and 1.5 mM CaCl₂, at 10⁶ cells/ml and kept on ice. The buffer was depleted of endotoxin by affinity chromatography over columns containing polymyxin B sepharose (Detoxi-gel, Pierce Scientific, Rockford, IL) and autoclaved for one hour. All plastic wear was autoclaved for at least 45 minutes.

30 Snežna L-Selectin Shedding Assay: Cells suspended in HSA and CaCl₂ containing HHB at 10⁶ cells/ml were immunofluorescently labeled for 45 min on ice with Leu-8-FITC (IgG2a; Becton-Dickinson Monoclonal Antibodies, Lincoln Park, NJ), a fluorescent mAb which recognizes L-selectin, at a final concentration of 0.625 µg/ml. 200 µl of this prelabeled cell

suspension is used for each sample. The assay is preferably carried out in duplicate and contains:

- a) Ice control.
- b) Temperature control.
- 5 c) Solvent control: (b) + solvent of the drug to be tested.
- d) fMLP at 100nM.
- e) a known PDI inhibitor, e.g. PAO or DTNB.
- f) Sample drugs at various concentrations (optional).

10

Samples (b) onwards were placed into a waterbath at 37°C, for about 10 minutes. The reaction was terminated by placing and keeping the samples on ice. The relative expression of the receptors was quantitated using a FACScan Flow Cytometer (such as Becton-Dickinson).

15

Controls: To show that cells are viable and normally responsive, neutrophils were activated with fMLP (formyl-methionyl-leucyl-phenylalanine; Sigma Chemical Co., St. Louis, MO) for 10 min at 37°C at a final concentration of 100nM. This releases at least 90% of all cell surface L-selectin as measured by the loss of fluorescently labeled L-selectin from neutrophils using FACScan. Lymphocytes do not respond to fMLP. Lymphocytes do shed their L-selectin in response to phorbol ester PMA (100nM), but do so only slowly (~30 min). To show that leucocytes respond normally to PDI inhibitors, the response of both neutrophils and lymphocytes to μ M concentrations of phenylarsine oxide (PAO, Sigma) was measured: Neutrophils shed most of their L-selectin in response to 1 μ M PAO within 10 min; lymphocytes required 5 μ M PAO to shed their L-selectin within 19 min. Alternatively, a known blocker of PDI, 5',5'-dithio-bis(2-nitrobenzoic acid) (DTNB, Sigma), can be used at 1mM concentration as a positive control.

20

25

30

5 To check for cell activation, the neutrophils are assayed for the characteristic increase in the cell surface Mac-1 expression. This is done by carrying out the above L-selectin shedding assay, but using unlabeled cells. At the end of the
10 37°C incubation period, neutrophils placed on ice and Leu-15-PE (IgG2a; Becton-Dickinson Monoclonal Antibodies), and a fluorescent mAb which recognizes the α -subunit (CD11b) of Mac-1 added at the final 1.25 μ g/ml concentration. Samples incubated with the antibody on ice for 45 minutes, and expression of the receptors thereafter quantitated with the FACScan. FMLP-treated sample served as a positive control; samples treated with fMLP increased their cell surface expression 3-10 fold compared to the ice control.

15 The effect of the putative PDI inhibitors on other cell surface molecules was further assessed using either analogous direct immunofluorescence or indirect immunofluorescence. For example, after the treatment of unlabeled cells with the appropriate reagents, the cells incubated for 40 minutes at 4°C with appropriate antibodies. The antibodies against CD14, CD16
20 (both at 10 μ g/ml; Dako Corporation, Carpinteria, CA), CD43 (8 μ g/ml; IgG2a; Camfolio (Becton-Dickinson), San Jose, CA), CD54 (8 μ g/ml; Biosource International, Camarillo, CA), PSGL-1 (PL1; IgG1; 10 μ g/ml; Dr. Rodger McEver, University of Oklahoma). After incubation the cells were washed by centrifugation for 10
25 minutes at 400g at 4°C. The second antibody, goat-anti-mouse IgG-FITC (GAM-FITC) polyclonal Ab (Becton-Dickinson Antibodies, Lincoln Park, NJ) at a concentration of 6.25 μ g/ml was added and cells were incubated an additional 20 minutes at 4°C. After a final wash, the specific labeling for each antibody was analyzed
30 by flow cytometry.

35 Time course experiments. For these experiments, isolated neutrophils or lymphocytes were warmed to 37°C and a zero point sample was withdrawn and placed on ice. The putative PDI inhibitor was then added. Cell samples were withdrawn at one minute intervals and placed on ice. The cells were then labeled for 40 minutes with Leu8-FITC on ice and L-selectin expression measured by the FACScan.

EXAMPLE IIGeneral Protocol for Directly Assessing the Ability of PDI Inhibitors to Block HIV Entry into Cells

5 The protocol used by NIH, Department of Health and Human Service "Anti-HIV Drug Testing System" infra is designed to detect agents acting at any stage of the virus reproductive cycle. As is pointed out in this description of the test, 10 certain compounds may not show activity in this test. Inhibitors of PDI, such as PAO and its derivatives, act at the stage of the viral entry which occurs within the first few (2-3) hours of the contact between the viral stock and the target cells. To assay 15 for the specific impact of a drug on viral entry, both the drug and the free virion should be removed from the cells after the infection period. The decrease in the number of the infected cells after the 6 days incubation period will be a reflection on the drug's inhibition of viral entry. This variation on the NIH protocol will additionally eliminate the potential toxic effects 20 associated with the long term exposure of the drug. The impact of inhibitors on HIV entry may otherwise be obscured by such long term toxicity. In the case of PAO/PAO* a long-term toxicity was anticipated and in spite of the superimposition of long-term 25 toxicity onto the outcome, PAO* did show anti-HIV activity in this assay. It is expected that about ~10uM PAO* will show a complete blockade of HIV entry when the above steps are followed in the protocol. PAO and other analogues are likely to have a similar effect.

30 Knowledge that a reagent (a PDI inhibitor) is effective at inhibiting the viral entry is of great value; and changes in drug design according to known principles can subsequently minimize potential toxicities. Since the target of inhibition is PDI, a cell surface protein, this may in many cases only require making the drug less membrane permeable. This is true 35 in the case of PAO, which, when made less membrane permeable (PAO*), nonetheless shows anti-HIV activity. Moreover, there are clinical situations which may require only a short exposure to the drug which blocks HIV entry and where long term treatment may not be necessary. One example would be treatment of an

individual only recently infected with HIV, as by a stick with an infected needle.

HIV Anti-HIV Drug Testing System

The Procedure:

25 1. Candidate agent is dissolved in dimethyl sulfoxide
(unless otherwise instructed) then diluted 1:100 in cell culture
medium before preparing serial half-log₁₀ dilutions. T4
lymphocytes (CEM cell line) are added and after a brief interval
HIV-1 is added, resulting in a 1:200 final dilution of the
compound. Uninfected cells with the compound serve as a toxicity
control, and infected and uninfected cells without the compound
30 serve as basic controls.

2. Cultures are incubated at 37° in a 5% carbon dioxide atmosphere for 6 days.

35 3. The tetrazolium salt, XTT, is added to all wells,
and cultures are incubated to allow formazan color development
by viable cells.

4. Individual wells are analyzed spectrophotometrically to quantitate formazan production, and in addition are viewed microscopically for detection of viable cells and confirmation of protective activity.

5 5. Drug-treated virus-infected cells are compared with drug-treated noninfected cells and with other appropriate controls (untreated infected and untreated noninfected cells, drug-containing wells without cells, etc.) on the same plate.

10 6. Data are reviewed in comparison with other tests done at the same time and a determination about activity is made.

15 [#]Weislow, O.W., Kiser, R., Fine, D., Bader, J., Shoemaker, R.H., Boyd, M.R.: New soluble-formazan assay for HIV-1 cytopathic effects: application to high-flux screening of synthetic and natural products for AIDS-antiviral activity. J. Natl. Cancer Inst. 81;577-586, 1989.

EXAMPLE III


1. Preparation of PAO*

20 Membrane impermeable derivatives of PAO were designed, prepared, and tested. These derivatives, referred to herein as PAO*s, have a charged ligand attached to the aromatic amine of 4-aminophenylarsenoxide (4-APAO). The charge on this terminal ligand is believed to prevent the molecule from passing through 25 the cell membrane.

30 A number of potential synthetic PAO* targets exist. In the planning of these preparations, the difficulties of working with organometallic reagents must be noted. First, conditions must be selected so that the arsenic is not inadvertently oxidized from As(III) to As(V). Second, because of the metal content as well as the charged portion of the PAO* molecule, many standard organic chemistry purification and characterization techniques are inoperable.

35 The first PAO* derivative was prepared through the reaction of 4-APAO with 2-bromoethanesulfonic acid sodium salt in 1:1 DMSO:water. This was carried out in the presence of aqueous Na₂CO₃ at 90° for 8-12 hours.


23



10 Column and thin layer chromatographies for purification and purity assessment do not work with this system. Gas chromatography-mass-spectrometry as well as more direct mass spectrometry ionization methods have also proven ineffective due to the low volatility of the tested compound. Reversed phase HPLC usingocratic water and UV detection provided a reasonable assay 15 for this first PAO* derivative. Along with proton NMR analysis, data confirmed both the structure and purity of PAO*.

2. Additional Versions of PAO*

20 An additional membrane-impermeable derivative of PAO*, PAODMPS* was prepared according to the following reaction scheme. The compound was shown to induce L-selectin shedding (Fig. 2).



Following the successful purification of this initial PAO* derivative, other PAO* derivatives are prepared and tested.

The following chemical modifications are particularly interesting:

5 A) The addition of more than one charged entity to the prototypical PAO molecule may impart a further decrease in membrane permeability. Structure A has two anionic SO_3^- groups.

10 B) The addition of alkyl chains of various lengths between the amino nitrogen and the charged group may impart varying degrees of partial membrane impermeability (139). The longer chains may allow the aromatic portion of the compound to permeate the membrane while the charged portion of the molecule remains outside the membrane. Various chain lengths allow for various depths of penetration through the membrane (Structure B).




15 C) Additional control over molecular geometry may be obtained by the incorporation of a more rigid aromatic ligand bearing the charged entity (140). This allows for a more specific control over sterics and electronics than is allowed through the use of simple alkyl chains (Structure C).

20 D) Negatively charged ligand: A quaternary ammonium salt imparts a positive charge to the ligand. The implications of positive versus negative charges on the PAO* ligand have not yet been examined in this system (Structure D).

25 E) The phenyl ring in 4-amino PAO can be replaced with hetero-aromatic substituents, such as an isoxazolyl ring. The isoxazole is well known in medicinal chemistry to be amenable to a variety of substitution patterns (141, 142). Furthermore, an isoxazole can be heterolytically cleaved to the acylaziridine using photochemistry and therefore may be useful as a photoaffinity probe (Structure E) (143). Examples of A-E and further derivatives F-H with the arsenite conjugated to different ligands are illustrated below:



25

5




10

15




F) Beta-mercaptopropane sulfonic acid:

20



G) Cysteamine HCl:


25



30

H) Dimercaptopropane sulfonic acid:

35



A novel class of membrane-impermeable arsenoxide derivatives is generated on this basic principle. Conjugation of a membrane-impermeable compound to the arsenical via (di)thiols makes the compound membrane-impermeable until the compound reacts with the vicinal dithiol of PDI and the original adduct is reduced and released extracellularly. By conjugating ligands F-H to form membrane-impermeable PAO* derivatives, the derivative is fully restricted to the outside of the cells and non-toxic. The number of anti-trypanosomal drugs have been generated on this chemical principle. (Eur. J. Biochem. 221:285-95, 1994), but with one important difference: these anti-trypanosomal drugs need to enter the cells, so both sides of the active site arsenical are made extra membrane-permeable.

15

EXAMPLE IV

Method for Whole Blood Measurement of Inhibitor-Activity

Inhibitor in whole blood can be measured as follows:

20 Peripheral venous blood was diluted 1:10 with HHB buffer and treated with 1 μ M PAO for 20 min. at 37°C. L-selectin expression was measured by FACSscan analysis (*supra*) of LDS-751 and Leu8-FITC labelled cells (FIG. 4). For HIV treatment, activity is preferably measured by L-selectin expression on lymphocytes, rather than neutrophils.

25

Induction of L-selectin shedding in whole blood is useful as an assay to determine the inhibitor concentration required to block, e.g., leucocyte or lymphocyte PDI. This whole-blood ex-vivo assay is preferable to assays of purified leucocytes or lymphocytes for clinical use of the inhibitors.

30


WHAT IS CLAIMED IS:

1. A membrane-impermeable inhibitor of protein disulfide isomerase (PDI).

5

2. An inhibitor according to Claim 1 of the formula

10



15 wherein at least one of R and R' is a charged ligand containing from 1 to 6 carbon atoms.

3. An inhibitor according to Claim 2, wherein the charged ligand contains at least one sulfonate group.

20

4. An inhibitor according to Claim 2, wherein the ligand is a straight chain or branched alkyl group containing 1, 3, 4, or 6 carbon atoms and at least one sulfonate group.

25

5. An inhibitor according to Claim 2, wherein the ligand is an aryl group containing at least one sulfonate group.


6. The inhibitor of Claim 5, wherein the sulfonate group is attached to a ring carbon atom.

30

7. The inhibitor of Claim 6, wherein the sulfonate group is attached to the ring carbon atom via a C₁-C₆-alkylene group.

35


8. An inhibitor according to claim 1 of the formula



wherein R is H or alkyl.

9. An inhibitor according to Claim 1 of the formula

15



wherein at least one of R and R' is a charged ligand.

10. An inhibitor according to Claim 9, wherein the charged ligand contains at least one sulfonate group.

11. An inhibitor according to Claim 2 or 9, wherein one of R or R' is an uncharged H or C₁-C₆-alkyl ligand.

30 12. A method for inhibiting PDI compounds exposing cells expressing PDI to a compound according to any one of Claims 1-8 in an amount sufficient to inhibit PDI activity.

35 13. The method of Claim 12, wherein PDI activity is measured by assaying L-selectin shedding from leucocytes or lymphocytes.

14. A method for treating a mammal for a viral infection propagated by PDI-mediated virion entry into host cells comprising administering to the mammal phenylarsine oxide (PAO) or a compound according to any one of Claims 1-8 in an amount sufficient to inhibit viral propagation.

5. 15. The method of Claim 14, wherein the viral infection is an HIV infection.

10 16. A method for measuring the potency of a potential PDI inhibitor comprising assaying cell L-selectin shedding according to the Snežna L-Selectin Assay as a direct measure of inhibition potency.

15 17. The method of Claim 16, wherein leucocytes or lymphocytes are exposed to a potential PDI inhibitor, contacted with a labeled anti-L-selectin antibody and assayed for released L-selectin.

20 18. The method of Claim 16, wherein leucocytes or lymphocytes are prelabeled with a detectable anti-L-selectin antibody, contacted with a potential PDI inhibitor, and assayed for released selectin.

25 19. A method for determining optimum blood concentrations of a PDI inhibitor for treatment of a mammal for a viral infection according to Claim 14 or 15, comprising admixing a blood sample with PDI inhibitor and assaying for leucocyte L-selectin shedding.

1/6




FIG. 1

2/6

L-selectin shedding: PMN




FIG.2

3/6




FIG. 3

4/6




FIG. 4A

5/6




FIG. 4B

6/6




FIG. 4C

PATENT COOPERATION TREATY

PCT

09/424181

INTERNATIONAL SEARCH REPORT

(PCT Article 18 and Rules 43 and 44)

Applicant's or agent's file reference A-5840.PCT	FOR FURTHER ACTION	see Notification of Transmittal of International Search Report (Form PCT/ISA/220) as well as, where applicable, item 5 below.
International application No. PCT/US98/09795	International filing date (day/month/year) 14 MAY 1998	(Earliest) Priority Date (day/month/year) 14 MAY 1997
Applicant THE UNIVERSITY OF NEW MEXICO		

This international search report has been prepared by this International Searching Authority and is transmitted to the applicant according to Article 18. A copy is being transmitted to the International Bureau.

This international search report consists of a total of 2 sheets.

It is also accompanied by a copy of each prior art document cited in this report.

1. Certain claims were found unsearchable (See Box I).
2. Unity of invention is lacking (See Box II).
3. The international application contains disclosure of a nucleotide and/or amino acid sequence listing and the international search was carried out on the basis of the sequence listing
 - filed with the international application.
 - furnished by the applicant separately from the international application,
 - but not accompanied by a statement to the effect that it did not include matter going beyond the disclosure in the international application as filed.
 - transcribed by this Authority.
4. With regard to the title, the text is approved as submitted by the applicant.
 the text has been established by this Authority to read as follows:
5. With regard to the abstract,
 - the text is approved as submitted by the applicant.
 - the text has been established, according to Rule 38.2(b), by this Authority as it appears in Box III. The applicant may, within one month from the date of mailing of this international search report, submit comments to this Authority.
6. The figure of the drawings to be published with the abstract is:

Figure No. _____

 - as suggested by the applicant.
 - because the applicant failed to suggest a figure.
 - because this figure better characterizes the invention.

None of the figures.

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US98/09795

A. CLASSIFICATION OF SUBJECT MATTER

IPC(6) :A61K 31/285

US CL. :514/504

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 514/504; 423/617

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

APS, CAS Online

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A <input checked="" type="checkbox"/>	US 5,532,154 A (BROWN) 02 July 1996, cols 7-8.	1-19
A <input checked="" type="checkbox"/>	KALEF, E. et al., Arsenical-Based Affinity Chromatography of Vicinal Dithiol-Containing Proteins: Purification of L1210 Leukemia Cytoplasmic Proteins and the Recombinant Rat c-erb A beta1 T3 Receptor, Analytical Biochemistry 1993, Vol. 212, pages 325-334.	1-19

Further documents are listed in the continuation of Box C.

See patent family annex.

•	Special categories of cited documents:	"T"	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"A"	document defining the general state of the art which is not considered to be of particular relevance	"X"	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"E"	earlier document published on or after the international filing date	"Y"	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"L"	document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"&"	document member of the same patent family
"O"	document referring to an oral disclosure, use, exhibition or other means		
"P"	document published prior to the international filing date but later than the priority date claimed		

Date of the actual completion of the international search

10 AUGUST 1998

Date of mailing of the international search report

23 SEP 1998

Name and mailing address of the ISA/US
Commissioner of Patents and Trademarks
Box PCT
Washington, D.C. 20231Authorized officer
Appraiser Lawrence Jor
DAVID LUKTON

Facsimile No. (703) 305-3230

Telephone No. (703) 308-0196